CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Fracture risk increases following cancer therapies for advanced prostate cancer
Unlocking the potential of liquid biopsy applications in personalised care for older adults with cancer
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients
Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM
Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Use of bispecifics and CAR T cells in South America
Tailored to fit: New approaches in transplant-ineligible NDMM
Advancements in minimal residual disease detection in myeloma
Novel biomarkers in myeloma: CTCs and cfDNA